TipRanks
Advertisement
Advertisement

ACXP Stock Latest News

Advancing C. Difficile Program Supports Unchanged $31 Price Target and Buy Rating
RatingsAdvancing C. Difficile Program Supports Unchanged $31 Price Target and Buy Rating
6d ago
ACXP
Acurx enrolls first patient in clinical trial of Ibezapolstat in rCDI
PremiumThe Fly
Acurx enrolls first patient in clinical trial of Ibezapolstat in rCDI
6d ago
ACXP
Acurx registers to sell 1.5M shares of common stock for holders
PremiumThe Fly
Acurx registers to sell 1.5M shares of common stock for holders
27d ago
ACXP
Acurx announces FDA conditional approval of CIFBEZY as brand name for ibezapolst
PremiumThe Fly
Acurx announces FDA conditional approval of CIFBEZY as brand name for ibezapolst
2M ago
ACXP
Acurx receives patents for DNA Polymerase IIIC inhibitors in Mexico and Japan
PremiumThe Fly
Acurx receives patents for DNA Polymerase IIIC inhibitors in Mexico and Japan
2M ago
ACXP
Acurx reports Q2 EPS (53c) vs. ($1.89) last year
PremiumThe FlyAcurx reports Q2 EPS (53c) vs. ($1.89) last year
2M ago
ACXP
Acurx Pharmaceuticals Earnings Call Highlights Funding Risk
Premium
Company Announcements
Acurx Pharmaceuticals Earnings Call Highlights Funding Risk
2M ago
ACXP
ACXP Advances Ibezapolstat Trial in High-Risk C. Difficile Patients
Premium
Company Announcements
ACXP Advances Ibezapolstat Trial in High-Risk C. Difficile Patients
2M ago
ACXP
ACXP Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ACXP Earnings this Week: How Will it Perform?
2M ago
ACXP
Acurx partners with Leiden University Medical Center to develop its antibiotics
PremiumThe Fly
Acurx partners with Leiden University Medical Center to develop its antibiotics
2M ago
ACXP
Acurx announces outcome of meeting with FDA on ibezapolstat’s clinical program
PremiumThe Fly
Acurx announces outcome of meeting with FDA on ibezapolstat’s clinical program
2M ago
ACXP
Acurx’s ibezapolstat shows microbe preservation efficacy
PremiumThe Fly
Acurx’s ibezapolstat shows microbe preservation efficacy
3M ago
ACXP
Acurx Pharmaceuticals Charts Risky but Promising CDI Path
PremiumCompany AnnouncementsAcurx Pharmaceuticals Charts Risky but Promising CDI Path
5M ago
ACXP
Acurx reports Q1 EPS (62c) vs. ($2.15) last year
Premium
The Fly
Acurx reports Q1 EPS (62c) vs. ($2.15) last year
5M ago
ACXP
Acurx files to sell 1.65M shares of common stock for holders
Premium
The Fly
Acurx files to sell 1.65M shares of common stock for holders
5M ago
ACXP
Acurx files to sell 1.3M shares of common stock for holders
PremiumThe Fly
Acurx files to sell 1.3M shares of common stock for holders
5M ago
ACXP
Acurx announces $7.1M registered direct offering priced at-the-market
PremiumThe Fly
Acurx announces $7.1M registered direct offering priced at-the-market
6M ago
ACXP
Acurx Pharmaceuticals Secures New Financing to Advance Pipeline
PremiumCompany Announcements
Acurx Pharmaceuticals Secures New Financing to Advance Pipeline
6M ago
8K
ACXP
New to The Street announce re-signing of Acurx Pharmaceuticals
PremiumThe Fly
New to The Street announce re-signing of Acurx Pharmaceuticals
6M ago
ACXP
Acurx: KIPO grantes new patent covering DNA Polymerase IIIC inhibitors
PremiumThe FlyAcurx: KIPO grantes new patent covering DNA Polymerase IIIC inhibitors
6M ago
ACXP
Acurx price target lowered to $10 from $20 at Alliance Global
Premium
The Fly
Acurx price target lowered to $10 from $20 at Alliance Global
7M ago
ACXP
Acurx reports Q4 EPS (73c) vs. ($3.29) last year
Premium
The Fly
Acurx reports Q4 EPS (73c) vs. ($3.29) last year
7M ago
ACXP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >